Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Antineoplastic Agents
/ chemical synthesis
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Humans
Molecular Docking Simulation
Molecular Structure
Protein Kinase Inhibitors
/ chemical synthesis
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Pyridines
/ chemical synthesis
Pyrroles
/ chemical synthesis
Structure-Activity Relationship
Anticancer
B-RAF inhibitors
Kinase inhibitor
Pyrrolo[2,3-b]pyridine
SAR
Journal
Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
04
02
2020
revised:
04
04
2020
accepted:
05
04
2020
pubmed:
29
4
2020
medline:
2
6
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved
Identifiants
pubmed: 32340792
pii: S0968-0896(20)30314-X
doi: 10.1016/j.bmc.2020.115493
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Pyridines
0
Pyrroles
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
pyrrolo(2, 3-b)pyridine
QX4465NR9T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
115493Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.